CD8A and neoplasm: By contrast, tumours with a lower TMB, WNT pathway, CDH1, JAK2, ERBB2 and FGFR2 alterations as well as terminally differentiated exhausted CD8+ T-cells were pembrolizumab-insensitive [34].